Clinical Trials Browser

OTHER × zimberelimab × 1 year × Clear all

NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Recurrence

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

Melanoma

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

Urothelial Bladder Carcinoma

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT07424664 2026-02-20

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT07134556 2026-01-23

ADJUNCT

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07337447 2026-01-13

REWENEC 01

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04791839 2025-11-05

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05886634 2025-10-20

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Phase 2 Active not recruiting

Liposarcoma, Sarcoma

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT05024097 2025-08-27

PANTHER

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05632848 2025-07-21

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT05724563 2025-05-21

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT05915442 2025-05-20

SBRT-AMICO

Phase 2 Recruiting

Oligometastatic Prostate Cancer